J Clin Oncol 22: by American Society of Clinical Oncology INTRODUCTION
|
|
- Bertina Rose
- 7 years ago
- Views:
Transcription
1 VOLUME 22 NUMBER 16 AUGUST JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T The Microanatomic Location of Metastatic Melanoma in Sentinel Lymph Nodes Predicts Nonsentinel Lymph Node Involvement D.J. Dewar, B. Newell, M.A. Green, A.P. Topping, B.W.E.M. Powell, and M.G. Cook From the Department of Plastic and Reconstructive Surgery, St George s Hospital, London; and Department of Histopathology, Royal Surrey County Hospital, Guildford, Surrey, United Kingdom. Submitted December 26, 2003; accepted May 27, Presented in part at the British Association of Plastic Surgeons Winter Meeting, London, United Kingdom, November 27-29, 2002; the EORTC Melanoma Group Spring Meeting, Paris, France, April 11-12, 2003; and the Third Research Meeting on Melanoma, Milan, Italy, May 25-27, Authors disclosures of potential conflicts of interest are found at the end of this article. Address reprint requests to Donald Dewar, MB, BS, Department of Histopathology, Royal Surrey County Hospital, Egerton Rd, Guildford, Surrey GU2 7XX, United Kingdom; DJDewar@aol.com by American Society of Clinical Oncology A B S T R A C T Purpose Sentinel node biopsy is now widely accepted as the most accurate prognostic indicator in melanoma, and is important in guiding management of patients with clinical stage I or II disease. Patients with a positive sentinel node have conventionally undergone completion lymphadenectomy (CLND) of the involved basin, but only 20% have involvement beyond the sentinel node, suggesting that CLND may be unnecessary for the other 80% of patients. This study seeks to identify criteria that might be used to be more restrictive in selecting those who should undergo CLND. Methods A total of 146 patients were identified who had had a positive sentinel node biopsy for malignant melanoma. Their sentinel nodes and lymphadenectomy specimens were re-evaluated pathologically. The metastatic melanoma in each sentinel node was assessed according to its microanatomic location within the node (subcapsular, combined subcapsular and parenchymal, parenchymal, multifocal, or extensive), and this was correlated with the presence of involved nonsentinel nodes in the CLND. The depth of the metastases from the sentinel node capsule was also recorded. Results The metastatic deposits in the sentinel node were subcapsular in 26.0% of patients. None of these patients had any nonsentinel nodes involved on CLND. In the patients whose sentinel node metastases had a different microanatomic location, the rate of nonsentinel node involvement was 22.2% overall. Conclusion The microanatomic location of metastases within sentinel nodes predicts nonsentinel lymph node involvement. In patients with only subcapsular deposits in the sentinel node, it is possible that CLND could safely be avoided. J Clin Oncol 22: by American Society of Clinical Oncology X/04/ /$20.00 DOI: /JCO INTRODUCTION Sentinel node biopsy is now the standard of care for accurate staging of patients with clinical stage I or II malignant melanoma. 1 In published series, between 15% and 34% of patients undergoing sentinel node biopsy will have metastases within the sentinel node(s), depending on the inclusion criteria and the techniques used for preparation and histologic examination of the nodes. 2,3 These patients have been shown to have a greater risk of further disease and shorter survival than sentinel node negative patients. This is the strongest prognostic criterion for melanoma. 4 In addition, sentinel node status is used to determine subsequent therapy. It is usual for patients with a positive sentinel node to proceed to removal of the remaining lymph nodes within the affected basin, termed completion lymphadenectomy (CLND). The presence of melanoma metastases in nonsentinel nodes (NSN) from the CLND specimen occurs in only 10% to 30% of cases. 5 Given the morbidity associated with lymphadenectomy, various groups have tried to predict NSN involvement on the basis of histologic features of the primary melanoma. 5,6 Although the likelihood of NSN involvement 3345
2 Dewar et al increases with increasing Breslow thickness of the primary tumor, even melanomas less than 2 mm in thickness have an 11% risk of having NSN metastases. 5 Starz et al 7 have described a process for morphometric analysis of metastatic deposits within the sentinel node itself, and used this to predict NSN involvement much more accurately. An alternative classification, incorporating histologic features of both the primary melanoma and the sentinel node metastasis, has been developed by Reeves et al. 8 Our study describes a simpler, alternative method for categorizing sentinel node metastases, based on physiologic microanatomy, and correlates this with NSN involvement. METHODS Patients whose sentinel node(s) contained metastatic malignant melanoma were identified from the St George s Melanoma Unit (London, United Kingdom) database. Eligibility criteria and techniques for sentinel node biopsy in the St George s Melanoma Unit have been described elsewhere. 9 Briefly, patients presenting with clinical stage I or II malignant melanoma were offered sentinel node biopsy if the Breslow thickness of the primary tumor was greater than 1.0 mm. Patients with a Breslow thickness less than 1.0 mm were included if the melanoma was Clark s level III or more, showed evidence of regression, or was in vertical growth phase. Sentinel nodes were identified using a standard technique of preoperative dynamic lymphoscintigraphy using radiolabeled colloid, followed by intraoperative injection of vital blue dye and use of a hand-held gamma probe. The sentinel node specimens were processed as previously reported, 2,3 using a bivalving technique based on that of Cochran. They were examined by both conventional histology and immunohistochemistry. For the purposes of this study, some sentinel node specimens from the earlier part of the series (before the development of the current processing protocol) were re-evaluated by the senior author. If necessary further sections were cut and stained so that all patients were assessed using the same sectioning and processing protocol. The metastatic deposit within each sentinel node was classified as subcapsular, combined subcapsular and parenchymal, parenchymal, multifocal, or extensive (as described in Table 1 and Fig 1), and its maximum depth from the capsule was measured. When more than one positive sentinel node had been removed from a single lymph node basin, the most extensive and/or deepest metastatic deposit overall was used to categorize that basin. In the six patients in whom sentinel nodes from more than one lymph node Microanatomic Location Subcapsular Combined Parenchymal Multifocal Extensive Table 1. Definition of Microanatomic Locations Definition Metastasis confined to subcapsular sinus Subcapsular and parenchymal metastases Metastasis entirely within paracortical area of parenchyma Multiple discrete deposits (must include some parenchymal deposits) Any metastasis larger than 5 mm, any node with extracapsular spread basin were found to contain melanoma, only the first basin to be entered into the database was included in the final analysis, because of the inherent correlation between multiple basins from an individual patient. CLND specimens were retrieved and reassessed for the presence of metastases. The rate of NSN involvement was calculated for each sentinel node subtype. Statistical analysis was performed using the 2 test, the Mann-Whitney U test, the Kruskal-Wallis test, and Newcombe s method, as indicated in Tables 2 and 3. RESULTS Sentinel node and corresponding CLND specimens were retrieved for 146 lymph node basins in 146 patients. The mean age of the patients was 49.9 years, and 55.2% were male. Patient, primary tumor, and sentinel node characteristics are described in Table 2. Patient age and sex, and site of the CLND, were not related to either microanatomic location of the sentinel node metastasis or NSN involvement (Tables 2 and 3). The number of sentinel nodes classified into each microanatomic location is listed in Table 2, with 38 (26.0%) in the subcapsular category. Of the CLND specimens, 24 (16.4%) showed evidence of melanoma metastases in NSN. There was a significant correlation between the microanatomic location and NSN involvement (Table 2). No patient with only a subcapsular deposit had subsequent NSN metastases (95% CI, 0.0% to 11.4%). Depth of the metastatic deposit from the capsule of the sentinel node also was strongly correlated with NSN involvement (Tables 2 and 3). However, three of 24 patients (12.5%) with positive NSNs had deposits less than 1 mm in depth. The shallowest was only 0.6 mm (but in a multifocal pattern). Although there was a relationship between the Breslow thickness of the primary melanoma and the microanatomic location of the sentinel node metastasis (Table 2), Breslow thickness was not significantly correlated with NSN involvement (Table 3). DISCUSSION This study categorizes metastases according to their microanatomic location within the sentinel node. It demonstrates that, for patients with sentinel nodes in which metastases are confined to a subcapsular site, the probability of NSN involvement is extremely low (zero in this series). This raises the question of whether these patients could safely be spared CLND and its associated morbidity. It is not surprising that the extent of the sentinel node metastasis predicts nonsentinel lymph node involvement, given that microscopic and macroscopic nodal involvement are known to have different prognostic significance. 10,11 This is recognized in the recent revision of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma, 12 which differentiates between micro- and macrometastases in the N classification JOURNAL OF CLINICAL ONCOLOGY
3 Microanatomic Location of Metastatic Melanoma Fig 1. Microanatomic locations of metastatic melanoma within sentinel nodes. (A) Subcapsular; (B) combined; (C) parenchymal; (D) multifocal; (E) extensive
4 Dewar et al Table 2. Patient, Primary Tumor, and Sentinel Node Characteristics, and NSN Positivity by Microanatomic Location Characteristic Total Subcaps Comb Parench Multifocal Extensive P No % Sex, % Male Female Age, years Mean , % , % Breslow of primary, mm 1.0, % , % , % , % Mean Range SD Basin, % Axilla Groin Neck Other Depth of SN metastasis, mm Mean Range SD Positive NSN No % % CI, % 11.0 to to to to to to 66.0 Abbreviations: NSN, nonsentinel node; subcaps, subcapsular; Comb, combined; Parench, parenchymal; SD, standard deviation; SN, sentinel node. 2 test. Kruskal-Wallis test. Newcombe s method. Previous studies have estimated the size of sentinel node metastases to predict NSN involvement. Starz et al 7 proposed a classification based on the depth of the metastasis from the capsule and the number of 1-mm slices containing melanoma. Although a correlation between the classification by Starz et al and NSN involvement exists, subsequent study on a larger group of patients has shown that it does not predict NSN metastasis with complete reliability, given that a small group of patients with metastases less than 1 mm in depth shows NSN involvement (H. Starz, personal communication, April, 2002). Reeves et al 8 have devised a scoring system based on the extent of the tumor within the sentinel node and whether the primary melanoma is ulcerated. For patients with nonulcerated primary tumors and less than 2 mm of tumor in the sentinel node, there is a low probability of NSN metastasis (zero in their published series). In the present study, however, six of 24 (25%) of the NSN-positive patients had a sentinel node metastasis of less than 2 mm in maximum dimension. This concurs with earlier work by Carlson et al, 12 suggesting that size of the sentinel node metastasis is not a reliable predictor of NSN involvement. Reeves et al 8 also found a correlation between Breslow thickness of the primary melanoma and NSN status. Our study supports the alternative view, that Breslow thickness and NSN status are not significantly related. 5,6 This question warrants further investigation. Ulceration of the primary tumor was not reported routinely in the early part of the St George s series and therefore has not been investigated as a factor in this study. The proposed microanatomic classification predicts NSN involvement more accurately than size and depth alone because, in several patients, small deposits (some consisting of only a few cells) were associated with NSN metastasis, but none was confined to a subcapsular location. In contrast, no patient with only a subcapsular deposit was found to have tumor in NSNs. Although this study confirms the correlation between depth of the sentinel node metastasis from the capsule and NSN involvement, 12.5% of patients with positive NSNs had metastases less than 1 mm 3348 JOURNAL OF CLINICAL ONCOLOGY
5 Microanatomic Location of Metastatic Melanoma Table 3. Patient, Tumor, and SN Characteristics by NSN Status Characteristic Negative NSN Positive NSN No % Sex, % Male Female Age, years Mean , % , % Breslow of primary, mm 1.0, % , % , % , % Mean Range SD Basin, % Axilla Groin Neck Other Depth of SN metastasis, mm Mean Range SD Abbreviations: SN, sentinel node; NSN, nonsentinel node; SD, standard deviation. 2 test. Mann-Whitney U test. P in depth. Depth alone, therefore, is not considered a sufficiently reliable predictor of NSN involvement to identify patients who might safely avoid CLND. Furthermore, the proposed microanatomic classification has a physiologic basis, with metastatic melanoma being presumed to enter a node via the afferent lymphatics into the subcapsular sinus, before passing into the paracortex, and ultimately replacing large parts of the node. This is reflected in the steadily increasing mean depth of metastatic deposits, and increased frequency of NSN metastases, on progression through the microanatomic categories (Table 2). The classification is simpler to learn and easier to use than the more complex micromorphometric techniques, and involves no additional cost. Given the controversy surrounding the influence of Breslow thickness on NSN status, it is also advantageous that the classification does not depend on histologic characteristics of the primary melanoma. This study was not designed to investigate differences in survival between different microanatomic locations of sentinel node metastases. Whether it is indeed safe not to perform CLND in patients with metastases confined to the subcapsular zone in sentinel nodes would need to be addressed in a properly designed and, ideally, randomized trial. It is recommended, in the meantime, that the microanatomic location of the metastases becomes a routine part of the histopathologic reporting of positive sentinel nodes. Authors Disclosures of Potential Conflicts of Interest The authors indicated no potential conflicts of interest. REFERENCES 1. WHO: WHO declares lymphatic mapping to be the standard of care for melanoma. Oncology 13:288, Cook MG, Green MA, Anderson B, et al: EORTC Melanoma Group: The development of optimal pathological assessment of sentinel lymph nodes for melanoma. J Pathol 200: , Ruiter DJ, Spatz A, van den Oord JJ, et al: Pathology Committee of the European Organization Research and Treatment of Cancer (EORTC) Melanoma Group: Pathologic staging of melanoma. Semin Oncol 29: , Gershenwald JE, Thompson W, Mansfield PF, et al: Multi-institutional melanoma lymphatic mapping experience: The prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 17: , McMasters KM, Wong SL, Edwards MJ, et al: Frequency of nonsentinel lymph node metastasis in melanoma. Ann Surg Oncol 9: , Wagner JD, Gordon MS, Chuang TY, et al: Predicting sentinel and residual lymph node basin disease after sentinel lymph node biopsy for melanoma. Cancer 89: , Starz H, Balda BR, Kramer KU, et al: A micromorphometry-based concept for routine classification of sentinel lymph node metastases and its clinical relevance for patients with melanoma. Cancer 91: , Reeves ME, Delgado R, Busam KJ, et al: Prediction of nonsentinel lymph node status in melanoma. Ann Surg Oncol 10:27-31, Topping AP, Dewar DJ, Rose V, et al: Five years of sentinel node biopsy for melanoma: The St George s Melanoma Unit experience. Br J Plast Surg 57:97-104, Balch CM, Soong SJ, Gershenwald JE, et al: Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 19: , Carlson GW, Murray DR, Lyles RH, et al: The amount of metastatic melanoma in a sentinel node: Does it have prognostic significance? Ann Surg Oncol 10: , Balch CM, Buzaid AC, Soong SJ, et al: Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19: ,
Observation After a Positive Sentinel Lymph Node Biopsy in Patients with Melanoma
Ann Surg Oncol (2014) 21:3117 3123 DOI 10.1245/s10434-014-3758-7 ORIGINAL ARTICLE MELANOMAS Observation After a Positive Sentinel Lymph Node Biopsy in Patients with Melanoma Zubin M. Bamboat, MD 1, Ioannis
More informationSentinel Lymph Node Mapping for Endometrial Cancer. Locke Uppendahl, MD Grand Rounds
Sentinel Lymph Node Mapping for Endometrial Cancer Locke Uppendahl, MD Grand Rounds Endometrial Cancer Most common gynecologic malignancy in US estimated 52,630 new cases in 2014 estimated 8,590 deaths
More informationPathologic Assessment Of The Breast And Axilla After Preoperative Therapy
Pathologic Assessment Of The Breast And Axilla After Preoperative Therapy W. Fraser Symmans, M.D. Associate Professor of Pathology UT M.D. Anderson Cancer Center Pathologic Complete Response (pcr) Proof
More informationHow to treat early gastric cancer. Surgery
How to treat early gastric cancer Surgery Mark I. van Berge Henegouwen Department of Surgery, AMC, Amsterdam Director upper GI surgical unit Academic Medical Center Upper GI surgery at AMC 100 oesophagectomies
More informationRESEARCH EDUCATE ADVOCATE. Just Diagnosed with Melanoma Now What?
RESEARCH EDUCATE ADVOCATE Just Diagnosed with Melanoma Now What? INTRODUCTION If you are reading this, you have undergone a biopsy (either of a skin lesion or a lymph node) or have had other tests in which
More informationPAPER. Surgical Management of the Groin Lymph Nodes in Melanoma in the Era of Sentinel Lymph Node Dissection
PAPER Surgical Management of the Groin Lymph Nodes in Melanoma in the Era of Sentinel Lymph Node Dissection Richard Essner, MD; Randall Scheri, MD; Maihgan Kavanagh, MD; Hitoe Torisu-Itakura, MD, PhD;
More informationBreast cancer close to the nipple: Does this carry a higher risk ofaxillary node metastasesupon diagnosis?
Breast cancer close to the nipple: Does this carry a higher risk ofaxillary node metastasesupon diagnosis? Erin I. Lewis, BUSM 2010 Cheri Nguyen, BUSM 2008 Priscilla Slanetz, M.D., MPH Al Ozonoff, Ph.d.
More informationChapter 2 Staging of Breast Cancer
Chapter 2 Staging of Breast Cancer Zeynep Ozsaran and Senem Demirci Alanyalı 2.1 Introduction Five decades ago, Denoix et al. proposed classification system (tumor node metastasis [TNM]) based on the dissemination
More informationSUNY DOWNSTATE MEDICAL CENTER SURGERY GRAND ROUNDS February 28, 2013 VERENA LIU, MD ROSEANNA LEE, MD
SUNY DOWNSTATE MEDICAL CENTER SURGERY GRAND ROUNDS February 28, 2013 VERENA LIU, MD ROSEANNA LEE, MD Case Presentation 35 year old male referred from PMD with an asymptomatic palpable right neck mass PMH/PSH:
More informationThe lymphatic system consists of a network of vessels
IMAGING Whole-Body Lymphoscintigraphy Using Transmission Scans Martha Vallejo Mar, BBA, CNMT; Sonia Gee-Johnson, BS, CNMT; E. Edmund Kim, MD; and Donald A. Podoloff, MD Department of Nuclear Medicine,
More informationUpdate on Mesothelioma
November 8, 2012 Update on Mesothelioma Intro incidence and nomenclature Update on Classification Diagnostic specimens Morphologic features Epithelioid Histology Biphasic Histology Immunohistochemical
More informationRotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma
Rotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma Medical Expert: Breast Rotation Specific Competencies/Objectives 1.0 Medical History
More informationClinical Indications and Results Following Chest Wall Resection
Clinical Indications and Results Following Chest Wall Resection for Recurrent Malignant Pleural Mesothelioma Ali SO, Burt BM, Groth SS, DaSilva MC, Yeap BY, Richards WG, Baldini EH and Sugarbaker DJ. Division
More informationversion 1.0, approved June 15, 2002 I. Purpose Background Information and Definitions
Society of Nuclear Medicine Procedure Guideline for Lymphoscintigraphy and the Use of Intraoperative Gamma Probe for Sentinel Lymph Node Localization in Melanoma of Intermediate Thickness version 1.0,
More informationADJUVANT RADIATION FOR MALIGNANT MELANOMA
ADJUVANT RADIATION FOR MALIGNANT MELANOMA Effective Date: February 2014 The recommendations contained in this guideline are a consensus of the Alberta Cutaneous Tumour Team and are a synthesis of currently
More informationSurgical Management of Papillary Microcarcinoma 趙 子 傑 長 庚 紀 念 醫 院 林 口 總 院 一 般 外 科
Surgical Management of Papillary Microcarcinoma 趙 子 傑 長 庚 紀 念 醫 院 林 口 總 院 一 般 外 科 Papillary microcarcinoma of thyroid Definition latent aberrant thyroid occult thyroid carcinoma latent papillary carcinoma)
More informationA918: Prostate: adenocarcinoma
A918: Prostate: adenocarcinoma General facts of prostate cancer The prostate is about the size of a walnut. It is just below the bladder and in front of the rectum. The tube that carries urine (the urethra)
More informationCurrent Status and Perspectives of Radiation Therapy for Breast Cancer
Breast Cancer Current Status and Perspectives of Radiation Therapy for Breast Cancer JMAJ 45(10): 434 439, 2002 Masahiro HIRAOKA, Masaki KOKUBO, Chikako YAMAMOTO and Michihide MITSUMORI Department of Therapeutic
More informationThe Revised Melanoma Staging System and the Impact of Mitotic Rate
THE ME L A N O M A LET TER A PUBLICATION OF THE SKIN CANCER FOUNDATION PERRY ROBINS, MD, President www.skincancer.org FALL 2010, Vol. 28, No. 3 MARY STINE, Executive Director The Revised Melanoma Staging
More informationSurgical guidelines for the management of breast cancer
Available online at www.sciencedirect.com EJSO xx (2009) S1eS22 www.ejso.com Guidelines Surgical guidelines for the management of breast cancer Contents Association of Breast Surgery at BASO 2009 Introduction...
More informationThe New Edition (7 th ) AJCC Staging System for Breast Cancer A Summary of Key Changes
The New Edition (7 th ) AJCC Staging System for Breast Cancer A Summary of Key Changes Joseph Rabban MD MPH Associate Professor UCSF Pathology Department joseph.rabban@ucsf.edu June 2010 Introduction:
More informationIntegrating Chemotherapy and Liver Surgery for the Management of Colorectal Metastases
I Congresso de Oncologia D Or July 5-6, 2013 Integrating Chemotherapy and Liver Surgery for the Management of Colorectal Metastases Michael A. Choti, MD, MBA, FACS Department of Surgery Johns Hopkins University
More informationCOMMISSIONING. for ULTRA-RADICAL SURGERY ADVANCED OVARIAN CANCER
COMMISSIONING for ULTRA-RADICAL SURGERY in ADVANCED OVARIAN CANCER WHY THIS MUST HAPPEN PERSPECTIVE COMMISSIONING FOR WHO, FOR WHAT? Biological Basis Surgical Basis International and national standards
More informationTravel Distance to Healthcare Centers is Associated with Advanced Colon Cancer at Presentation
Travel Distance to Healthcare Centers is Associated with Advanced Colon Cancer at Presentation Yan Xing, MD, PhD, Ryaz B. Chagpar, MD, MS, Y Nancy You MD, MHSc, Yi Ju Chiang, MSPH, Barry W. Feig, MD, George
More informationProtein kinase C alpha expression and resistance to neo-adjuvant gemcitabine-containing chemotherapy in non-small cell lung cancer
Protein kinase C alpha expression and resistance to neo-adjuvant gemcitabine-containing chemotherapy in non-small cell lung cancer Dan Vogl Lay Abstract Early stage non-small cell lung cancer can be cured
More information7 th Edition Staging. AJCC 7 th Edition Staging. Disease Site Webinar. Melanoma of Skin. Overview. This webinar is sponsored by
AJCC 7 th Edition Staging Melanoma of Skin Donna M. Gress, RHIT, CTR Validating science. Improving patient care. This presentation was supported by the Cooperative Agreement Number DP13-1310 from The Centers
More informationChanges in Breast Cancer Reports After Second Opinion. Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain
Changes in Breast Cancer Reports After Second Opinion Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain Second Opinion in Breast Pathology Usually requested when a patient is referred
More informationL Lang-Lazdunski, A Bille, S Marshall, R Lal, D Landau, J Spicer
Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine and systemic chemotherapy in malignant pleural mesothelioma. A 10-year experience. L Lang-Lazdunski, A Bille, S Marshall, R Lal,
More informationCancer of the Cardia/GE Junction: Surgical Options
Cancer of the Cardia/GE Junction: Surgical Options Michael A Smith, MD Associate Chief Thoracic Surgery Center for Thoracic Disease St Joseph s Hospital and Medical Center Phoenix, AZ Michael Smith, MD
More informationTargeted Therapy What the Surgeon Needs to Know
Targeted Therapy What the Surgeon Needs to Know AATS Focus in Thoracic Surgery 2014 David R. Jones, M.D. Professor & Chief, Thoracic Surgery Memorial Sloan Kettering Cancer Center I have no disclosures
More informationLymphatic Mapping Techniques and Sentinel Lymph Node Biopsy in Breast Cancer
Surg Clin N Am 87 (2007) 353 364 Lymphatic Mapping Techniques and Sentinel Lymph Node Biopsy in Breast Cancer Erika A. Newman, MD a, Lisa A. Newman, MD, MPH, FACS b, * a Department of Surgery, University
More informationHow to report Upper GI EMR/ESD specimens
Section of Pathology and Tumour Biology How to report Upper GI EMR/ESD specimens Dr.H.Grabsch Warning. Most of the criteria, methodologies, evidence presented in this talk are based on studies in early
More informationJ Clin Oncol 23:6149-6156. 2005 by American Society of Clinical Oncology INTRODUCTION
VOLUME 23 NUMBER 25 SEPTEMBER 1 2005 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Outcome Analysis for Patients With Elevated Serum Tumor Markers at Postchemotherapy Retroperitoneal Lymph Node
More informationHistorical Basis for Concern
Androgens After : Are We Ready? Mohit Khera, MD, MBA Assistant Professor of Urology Division of Male Reproductive Medicine and Surgery Scott Department of Urology Baylor College of Medicine Historical
More informationThe Royal Marsden. Surgery for Gastric and GE Junction Cancer: primary palliative where and when? William Allum
The Royal Marsden Surgery for Gastric and GE Junction Cancer: primary palliative where and when? William Allum Any surgeon can cure Surgeon - dependent No surgeon can cure EMR D2 GASTRECTOMY H N SN. WEDGE
More information7. Prostate cancer in PSA relapse
7. Prostate cancer in PSA relapse A patient with prostate cancer in PSA relapse is one who, having received a primary treatment with intent to cure, has a raised PSA (prostate-specific antigen) level defined
More informationEffects of Herceptin on circulating tumor cells in HER2 positive early breast cancer
Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer J.-L. Zhang, Q. Yao, J.-H. Chen,Y. Wang, H. Wang, Q. Fan, R. Ling, J. Yi and L. Wang Xijing Hospital Vascular Endocrine
More informationChapter 6. Deep lymph node metastases in the groin significantly affect prognosis, particularly in sentinel node positive melanoma patients
Chapter 6 Deep lymph node metastases in the groin significantly affect prognosis, particularly in sentinel node positive melanoma patients M.G. Niebling, K.P. Wevers, A.J.H. Suurmeijer, R.J. van Ginkel,
More informationUnderstanding Metastatic Disease
Supported by an unrestricted educational grant from Pfizer Understanding Metastatic Disease Metastatic disease or metastases are phrases that mean the same as Secondary cancer. This means that the cancer
More informationOncology Annual Report: Prostate Cancer 2005 Update By: John Konefal, MD, Radiation Oncology
Oncology Annual Report: Prostate Cancer 25 Update By: John Konefal, MD, Radiation Oncology Prostate cancer is the most common cancer in men, with 232,9 new cases projected to be diagnosed in the U.S. in
More informationPANCREATIC AND PERIAMPULLARY TUMORS: PANCREATICODUODENECTOMY. Dr. Shailesh V. Shrikhande
PANCREATIC AND PERIAMPULLARY TUMORS: PANCREATICODUODENECTOMY Dr. Shailesh V. Shrikhande Associate Professor & Consultant Surgeon GI and HPB Surgical Oncology Tata Memorial Hospital, Mumbai INDIA HELICAL
More informationUnderstanding your pathology report
Understanding your pathology report 2 Contents Contents Introduction 3 What is a pathology report? 3 Waiting for your results 4 What s in a pathology report? 4 Information about your breast cancer 5 What
More informationPrinciples of Radiation Therapy A Bapsi Chakravarthy, MD Associate e P rofessor Professor Radiation Oncology
Principles of Radiation Therapy A Bapsi Chakravarthy, MD Associate Professor Radiation Oncology Disclosure Information I have no financial relationships to disclose relevant to the conten of this presentation.
More informationPET. Can we afford PET-CT. Positron annihilation. PET-CT scanner. PET detection
PET-CT Can we afford PET-CT John Buscombe New technology Combines functional information-pet anatomical information-ct Machine able to perform both studies in single imaging episode PET imaging depends
More informationBRAF in the diagnostic evaluation of thyroid nodules
Symposium 13 Molecular markers in thyroid cancer: current role in clinical practice BRAF in the diagnostic evaluation of thyroid nodules Laura Fugazzola University of Milan, Italy Papillary carcinoma BRAF
More informationUpdate on thyroid cancer surveillance and management of recurrent disease. Minimally invasive thyroid surgery
Update on thyroid cancer surveillance and management of recurrent disease Minimally invasive thyroid surgery July 2006 Michael W. Yeh, MD Program Director, Endocrine Surgery Assistant Professor, David
More informationManagement of Postmenopausal Women with T1 ER+ Tumors: Options and Tradeoffs. Case Study. Surgery. Lumpectomy and Radiation
Management of Postmenopausal Women with T1 ER+ Tumors: Options and Tradeoffs Michael Alvarado, MD Associate Professor of Surgery University of California San Francisco Case Study 59 yo woman with new palpable
More informationLatest Oncologic Strategies for Well-Differentiated Thyroid Carcinoma
Latest Oncologic Strategies for Well-Differentiated Thyroid Carcinoma April 2008 Michael W. Yeh, MD Program Director, Endocrine Surgery Assistant Professor of Surgery and Medicine David Geffen School of
More informationMale. Female. Death rates from lung cancer in USA
Male Female Death rates from lung cancer in USA Smoking represents an interesting combination of an entrenched industry and a clearly drug-induced cancer Tobacco Use in the US, 1900-2000 5000 100 Per Capita
More informationINTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER Prospective Mesothelioma Staging Project
INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER Prospective Mesothelioma Staging Project Data Forms and Fields in CRAB Electronic Data Capture System - Reduced Set - Pivotal data elements for developing
More informationIl percorso diagnostico del nodulo tiroideo: il ruolo dell analisi molecolare
Il percorso diagnostico del nodulo tiroideo: il ruolo dell analisi molecolare Maria Chiara Zatelli Sezione di Endocrinologia Direttore: Prof. Ettore degli Uberti Dipartimento di Scienze Mediche Università
More informationLoco-regional Recurrence
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer AGO AGO e. e. V. V. Loco-regional Recurrence Loco-regional Recurrence Version 2002: Brunnert / Simon Versions 2003 2012: Audretsch
More informationTable of Contents. Data Supplement 1: Summary of ASTRO Guideline Statements. Data Supplement 2: Definition of Terms
Definitive and Adjuvant Radiotherapy in Locally Advanced Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation
More informationManagement of Peritoneal Metastases (PM) from colorectal cancers: New Perspectives. Dominique ELIAS
Management of Peritoneal Metastases (PM) from colorectal cancers: New Perspectives Dominique ELIAS Declaration of interest BOARDS Congress and teaching 0 Merck 0 Ipsen Novartis Sanofi Trials The peritoneum
More informationHOVON Staging and Response Criteria for Non-Hodgkin s Lymphomas Page 1
HOVON Staging and Response Criteria for Non-Hodgkin s Lymphomas Page 1 This document describes the minimally required staging and evaluation procedures and response criteria that will be applied in all
More informationLymph Nodes and Cancer What is the lymph system?
Lymph Nodes and Cancer What is the lymph system? Our bodies have a network of lymph vessels and lymph nodes. (Lymph is pronounced limf.) This network is a part of the body s immune system. It collects
More informationProstate cancer. Christopher Eden. The Royal Surrey County Hospital, Guildford & The Hampshire Clinic, Old Basing.
Prostate cancer Christopher Eden The Royal Surrey County Hospital, Guildford & The Hampshire Clinic, Old Basing. Screening Screening men for PCa (prostate cancer) using PSA (Prostate Specific Antigen blood
More informationProtocol for the Examination of Specimens from Patients with Melanoma of the Skin
Protocol for the Examination of Specimens from Patients with Melanoma of the Skin Protocol applies to melanoma of cutaneous surfaces only. Based on AJCC/UICC TNM, 7th edition Protocol web posting date:
More informationThyroid Cancer: Resection, Dissection, Surveillance and Recurrence. Cord Sturgeon, MD
Thyroid Cancer: Resection, Dissection, Surveillance and Recurrence Cord Sturgeon, MD Associate Professor of Surgery Northwestern University Feinberg School of Medicine Director of Endocrine Surgery Chicago,
More informationThe common feature of all melanomas is the cell of origin, the
1664 COMMUNICATION The American College of Surgeons Commission on Cancer and the American Cancer Society The National Cancer Data Base Report on Cutaneous and Noncutaneous Melanoma A Summary of 84,836
More informationOBJECTIVES By the end of this segment, the community participant will be able to:
Cancer 101: Cancer Diagnosis and Staging Linda U. Krebs, RN, PhD, AOCN, FAAN OCEAN Native Navigators and the Cancer Continuum (NNACC) (NCMHD R24MD002811) Cancer 101: Diagnosis & Staging (Watanabe-Galloway
More informationFrozen Section Diagnosis
Frozen Section Diagnosis Dr Catherine M Corbishley Honorary Consultant Histopathologist St George s Healthcare NHS Trust and lead examiner final FRCPath Practical 2008-2011 Frozen Section Diagnosis The
More informationImage. 3.11.3 SW Review the anatomy of the EAC and how this plays a role in the spread of tumors.
Neoplasms of the Ear and Lateral Skull Base Image 3.11.1 SW What are the three most common neoplasms of the auricle? 3.11.2 SW What are the four most common neoplasms of the external auditory canal (EAC)
More informationCutaneous Melanoma: Prognostic Factors
The clinical and histologic factors related to outcomes in localized and metastatic cutaneous melanoma are reviewed. Bernard Jean Corneille Pothast, 1882-1966. Playing with Baby. Oil on canvas, 20 24¼.
More informationPET/CT in Lung Cancer
PET/CT in Lung Cancer Rodolfo Núñez Miller, M.D. Nuclear Medicine and Diagnostic Imaging Section Division of Human Health International Atomic Energy Agency Vienna, Austria GLOBOCAN 2012 #1 #3 FDG-PET/CT
More informationManagement of low grade glioma s: update on recent trials
Management of low grade glioma s: update on recent trials M.J. van den Bent The Brain Tumor Center at Erasmus MC Cancer Center Rotterdam, the Netherlands Low grades Female, born 1976 1 st seizure 2005,
More informationUnderstanding Your Diagnosis of Endometrial Cancer A STEP-BY-STEP GUIDE
Understanding Your Diagnosis of Endometrial Cancer A STEP-BY-STEP GUIDE Introduction This guide is designed to help you clarify and understand the decisions that need to be made about your care for the
More informationTreating Melanoma S kin Cancer A Quick Guide
Treating Melanoma Skin Cancer A Quick Guide Contents This is a brief summary of the information on Treating melanoma skin cancer from our website. You will find more detailed information on the website.
More informationReport series: General cancer information
Fighting cancer with information Report series: General cancer information Eastern Cancer Registration and Information Centre ECRIC report series: General cancer information Cancer is a general term for
More informationHistopathology of Colorectal Cancer after Neoadjuvant Chemoradiation Therapy
The Open Pathology Journal, 2009, 3, 91-98 91 Open Access Histopathology of Colorectal Cancer after Neoadjuvant Chemoradiation Therapy Maura O Neil * and Ivan Damjanov Department of Pathology and Laboratory
More informationKIDNEY FUNCTION RELATION TO SIZE OF THE TUMOR IN RENAL CELL CANCINOMA
KIDNEY FUNCTION RELATION TO SIZE OF THE TUMOR IN RENAL CELL CANCINOMA O.E. Stakhvoskyi, E.O. Stakhovsky, Y.V. Vitruk, O.A. Voylenko, P.S. Vukalovich, V.A. Kotov, O.M. Gavriluk National Canсer Institute,
More informationThese rare variants often act aggressively and may respond differently to therapy than the more common prostate adenocarcinoma.
Prostate Cancer OVERVIEW Prostate cancer is the second most common cancer diagnosed among American men, accounting for nearly 200,000 new cancer cases in the United States each year. Greater than 65% of
More informationPrognostic and Predictive Factors in Breast Cancer Kyle T. Bradley, MD, MS CAP Cancer Committee
Prognostic and Predictive Factors in Breast Cancer Kyle T. Bradley, MD, MS CAP Cancer Committee Breast cancer is the most common malignant tumor in American women and is second only to lung cancer as a
More informationIndividual Prediction
Individual Prediction Michael W. Kattan, Ph.D. Professor of Medicine, Epidemiology and Biostatistics, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University Chairman, Department
More informationCANCER PULMON: ESTADIOS INICIALES POSTMUNDIAL PULMON DENVER 2015. 8-10-2015.Manuel Cobo Dols S. Oncología Médica HU Málaga Regional y VV
CANCER PULMON: ESTADIOS INICIALES POSTMUNDIAL PULMON DENVER 2015 8-10-2015.Manuel Cobo Dols S. Oncología Médica HU Málaga Regional y VV Meta-analisis LACE: adyuvancia vs no adyuvancia Pignon JP, et al.
More informationTitle: Immunohistochemical staining of radixin and moesin in prostatic adenocarcinoma
Author's response to reviews Title: Immunohistochemical staining of radixin and moesin in prostatic adenocarcinoma Authors: Tanner L Bartholow (bartholow.tanner@medstudent.pitt.edu) Uma R Chandran (chandranur@msx.upmc.edu)
More informationLocal control in ductal carcinoma in situ treated by excision alone: incremental benefit of larger margins
The American Journal of Surgery 190 (2005) 521 525 George Peter s Award Winner Local control in ductal carcinoma in situ treated by excision alone: incremental benefit of larger margins Heather R. MacDonald,
More informationEvidence tabel Lokaal palliatieve behandelingen
Auteurs, jaartal Mate van bewijs Studie type Follow-up Populatie (incl. steekproef-grootte) Patienten kenmerken Interventie Controle Resultaten Conclusie Opmerkingen, commentaar Hartgrink, 2002 The Netherlands
More informationUs TOO University Presents: Understanding Diagnostic Testing
Us TOO University Presents: Understanding Diagnostic Testing for Prostate Cancer Patients Today s speaker is Manish Bhandari, MD Program moderator is Pam Barrett, Us TOO International Made possible by
More informationMelanoma The Skin Understanding Cancer
Melanoma A form of cancer that begins in melanocytes (cells that make the pigment melanin). It may begin in a mole (skin melanoma), but can also begin in other pigmented tissues, such as in the eye or
More informationCytoreduction and hyperthermic intraperitoneal chemotherapy for the treatment of pseudomyxoma
Medical Policy Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Pseudomyxoma Peritonei and Peritoneal Carcinomatosis of Gastrointestinal Origin, and Peritoneal Mesothelioma
More informationHow To Compare The Effects Of A Hysterectomy And A Hysterectomy
A RANDOMIZED TRIAL COMPARING RADICAL HYSTERECTOMY AND PELVIC NODE DISSECTION VS SIMPLE HYSTERECTOMY AND PELVIC NODE DISSECTION IN PATIENTS WITH LOW RISK EARLY STAGE CERVICAL CANCER A Gynecologic Cancer
More informationReceptor conversion in distant breast cancer metastases. Breast cancer metastases: A spitting image of their primary?
Receptor conversion in distant breast cancer metastases Breast cancer metastases: A spitting image of their primary? Introduction Breast cancer is the leading cause of female cancer death worldwide (13,000
More informationOklahoma Facts CPT. Definitions. Mohs Micrographic Surgery. What Does That Mean? Billing and Coding for Mohs Surgery
Billing and Coding for Mohs Surgery Cindy L. Wilson Dermatology Associates of Tulsa Oklahoma Facts Per square mile, Oklahoma has more tornadoes than any other place in the world. The highest wind speed
More informationLocal Coverage Determination (LCD): MolDX: Breast Cancer Assay: Prosigna (L36125)
Local Coverage Determination (LCD): MolDX: Breast Cancer Assay: Prosigna (L36125) Contractor Information Contractor Name Palmetto GBA LCD Information Document Information LCD ID L36125 Original ICD-9 LCD
More informationUnderstanding Your Surgical Options For Breast Cancer
RADIATION THERAPY SYMPTOM MANAGEMENT CANCER INFORMATION Understanding Your Surgical Options For Breast Cancer In this booklet you will learn about: Role of surgery in breast cancer diagnosis and treatment
More informationHER2 Status: What is the Difference Between Breast and Gastric Cancer?
Ask the Experts HER2 Status: What is the Difference Between Breast and Gastric Cancer? Bharat Jasani MBChB, PhD, FRCPath Marco Novelli MBChB, PhD, FRCPath Josef Rüschoff, MD Robert Y. Osamura, MD, FIAC
More informationCoxsackievirus A21 (CAVATAK TM ) - mediated oncolytic immunotherapy in advanced melanoma patients
Coxsackievirus A21 (CAVATAK TM ) - mediated oncolytic immunotherapy in advanced melanoma patients Robert H.I. Andtbacka 1, Brendan Curti 2, Mark Grose 3, Len Post 4, Jeffrey Ira Weisberg 4 and Darren Shafren
More informationStage IV Renal Cell Carcinoma. Changing Management in A Comprehensive Community Cancer Center. Susquehanna Health Cancer Center
Stage IV Renal Cell Carcinoma Changing Management in A Comprehensive Community Cancer Center Susquehanna Health Cancer Center 2000 2009 Warren L. Robinson, MD, FACP January 27, 2014 Introduction 65,150
More information9. Discuss guidelines for follow-up post-thyroidectomy for cancer (labs/tests) HH
9. Discuss guidelines for follow-up post-thyroidectomy for cancer (labs/tests) HH Differentiated thyroid cancer expresses the TSH receptor on the cell membrane and responds to TSH stimulation by increasing
More informationThe Need for Accurate Lung Cancer Staging
The Need for Accurate Lung Cancer Staging Peter Baik, DO Thoracic Surgery Cancer Treatment Centers of America Oklahoma Osteopathic Association 115th Annual Convention Financial Disclosures: None 2 Objectives
More informationThe Whipple Operation for Pancreatic Cancer: Optimism vs. Reality. Franklin Wright UCHSC Department of Surgery Grand Rounds September 11, 2006
The Whipple Operation for Pancreatic Cancer: Optimism vs. Reality Franklin Wright UCHSC Department of Surgery Grand Rounds September 11, 2006 Overview Pancreatic ductal adenocarcinoma Pancreaticoduodenectomy
More informationObjectives. Mylene T. Truong, MD. Malignant Pleural Mesothelioma Background
Imaging of Pleural Tumors Mylene T. Truong, MD Imaging of Pleural Tumours Mylene T. Truong, M. D. University of Texas M.D. Anderson Cancer Center, Houston, TX Objectives To review tumors involving the
More informationDuctal carcinoma in situ (DCIS)
DIAGNOSIS: DCIS Ductal carcinoma in situ (DCIS) This factsheet gives information on an early form of breast cancer called ductal carcinoma in situ (DCIS). It explains what it is, how your breast is made
More informationOverview of Gynaecologic Cancer
Overview of Gynaecologic Cancer Stuart Salfinger Gynaecologic Oncologist St John of God Hospital King Edward Memorial Hospital Cervical Cancer Cervical Cancer Risk HPV Smoking?OCP Cervical Cancer Symptoms
More informationLung Cancer Treatment Guidelines
Updated June 2014 Derived and updated by consensus of members of the Providence Thoracic Oncology Program with the aid of evidence-based National Comprehensive Cancer Network (NCCN) national guidelines,
More informationSurvival and axillary recurrence following sentinel nodepositive breast cancer without completion axillary lymph node dissection the SENOMAC trial.
Survival and axillary recurrence following sentinel nodepositive breast cancer without completion axillary lymph node dissection the SENOMAC trial. A randomized study of patients with sentinel node macrometastasis
More informationGrade 4 Thrombocytopenia During. Predictor of Response in Melanoma but Not in Renal Cell Cancer.
Grade 4 Thrombocytopenia During Treatment with High-Dose IL-2 2 (HD IL-2) is a Predictor of Response in Melanoma but Not in Renal Cell Cancer. Timothy E. Bael, M.D. Bercedis L. Peterson, Ph.D. Karima Rasheed,
More informationMelanoma: assessment and management of melanoma
Melanoma: assessment and management of melanoma NICE guideline Draft for consultation, January 2015 If you wish to comment on this version of the guideline, please be aware that all the supporting information
More informationThe Di Bella Method (DBM) improves Survival, Objective Response and Performance Status in Breast Cancer
BIT's 4th World Cancer Congress 2011 People s Republic of China Dalian The Di Bella Method (DBM) improves Survival, Objective Response and Performance Status in treated with DBM therapy Retrospective observational
More information